Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Gains from Sales and Divestitures (2023 - 2024)

Mereo BioPharma (MREO) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • Quarterly Gains from Sales and Divestitures rose 166.89% to $1.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2024, up 166.89% year-over-year, with the annual reading at $1.3 million for FY2024, 166.89% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2024 was $1.3 million at Mereo BioPharma, roughly flat from $1.3 million in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.3 million in Q3 2024, with the low at $142583.0 in Q1 2024.